Nachrichten zur Idorsia AG Aktie

Idorsia presents at J.P. Morgan Healthcare Conference 2025 – fighting to create value for all stakeholders

Ad hoc announcement pursuant to Art. 53 LR…

Idorsia Aktie: Vor neuen Hürden

Die Idorsia-Aktie zeigt am 23. November 2024 eine volatile Entwicklung an der SIX Swiss Exchange. Nach einem anfänglichen Rückgang von…

Idorsia is advancing the treatment of hypertension with new data at the 2024 American Heart Association (AHA) Scientific Sessions

Allschwil, Switzerland – November 11, 2024…

Idorsia announces financial results for the first nine months of 2024

Ad hoc announcement pursuant to Art. 53 LR…

Invitation to Idorsias Half Year 2024 Financial Reporting webcast and conference call

Idorsia will publish its Half Year 2024 Financial Reporting on Thursday July 25, 2024, at 07:00 CEST.…

Idorsia’s JERAYGO (aprocitentan) approved in Europe as first and only ERA for the treatment of resistant hypertension

Allschwil, Switzerland – July 1, 2024Idorsia Ltd (SIX: IDIA) announced today that the European Commission (EC) has approved JERAYGO™ (aprocitentan)…

Idorsia’s novel treatment for chronic insomnia wins the prestigious Prix Galien Suisse 2024 innovation award in the ‘Primary & Speciality’ category

Allschwil, Switzerland – June 21, 2024Idorsia Ltd (SIX: IDIA) announced today that its novel treatment for chronic insomnia has been…

Idorsia holds its Annual General Meeting of Shareholders

Allschwil, Switzerland – June 13, 2024At today’s Annual General Meeting (AGM) of Idorsia Ltd (SIX: IDIA) held in Basel, Switzerland,…

GNW-Adhoc: New data with daridorexant to be presented at SLEEP 2024

^Allschwil, Switzerland - June 3, 2024 Idorsia Ltd (SIX: IDIA) today announced that new data with daridorexant, Idorsia's…

GNW-Adhoc: Data from the PRECISION study of aprocitentan to be presented at the European Society of Hypertension Annual Meeting 2024

^Allschwil, Switzerland - May 31, 2024 Idorsia Ltd (SIX: IDIA) today announced that data from the Phase…

GNW-Adhoc: Idorsia issues invitation to the 2024 Annual General Meeting of Shareholders

^Allschwil, Switzerland - May 23, 2024 Idorsia Ltd (SIX: IDIA) today issued the invitation to the upcoming…

Earnings call: Idorsia reports financials and progress on drug portfolio By Investing.com

Earnings call: Idorsia reports financials and progress on drug portfolio…

GNW-Adhoc: Idorsia announces changes to Idorsia Executive Committee and Board of Directors

^Ad hoc announcement pursuant to Art. 53 LR * Jean-Paul Clozel to retire as CEO…

GNW-Adhoc: Idorsia announces financial results for the first quarter 2024 - advancing the company with renewed vigor

^Ad hoc announcement pursuant to Art. 53 LR Allschwil, Switzerland - May 21, 2024 Idorsia Ltd (SIX: IDIA)…

GNW-Adhoc: Idorsia announces financial results for the full year of 2023 - Adapting the company to create sustainable value

^Ad hoc announcement pursuant to Art. 53 LR Allschwil, Switzerland - May 21, 2024 Idorsia Ltd (SIX:…

Idorsia announces financial results for the full year of 2023 – Adapting the company to create sustainable value

Ad hoc announcement pursuant to Art. 53 LR…

GNW-Adhoc: Invitation to Idorsia's Full Year 2023 and Q1 2024 Financial Reporting webcast and conference call

^Idorsia will publish its Full Year 2023 and Q1 2024 Financial Reporting on Tuesday May 21, 2024,…

GNW-Adhoc: Bondholders approve amended terms of the 2024 convertible bonds

^Ad hoc announcement pursuant to Art. 53 LR Bondholders approve amended terms of the 2024 convertible bonds …

GNW-Adhoc: Idorsia increases the consent fee in connection with the proposed restructuring of the 2024 convertible bond

^Ad hoc announcement pursuant to Art. 53 LR * The proposed consent fee will be…

Idorsia increases the consent fee in connection with the proposed restructuring of the 2024 convertible bond

Ad hoc announcement pursuant to Art. 53 LR…

GNW-Adhoc: JERAYGO (aprocitentan) recommended for approval in Europe for the treatment of resistant hypertension

^Ad hoc announcement pursuant to Art. 53 LR * Idorsia receives a positive opinion from…

GNW-Adhoc: Idorsia publishes an invitation to a bondholder meeting

^Ad hoc announcement pursuant to Art. 53 LR * A bondholder meeting will take place…

Idorsia publishes an invitation to a bondholder meeting

Ad hoc announcement pursuant to Art. 53 LR…

GNW-Adhoc: Idorsia publishes a Financial Status required for an upcoming bondholder meeting

^Ad hoc announcement pursuant to Art. 53 LR * Unaudited Financial Status as of March…

Idorsia publishes a Financial Status required for an upcoming bondholder meeting

Ad hoc announcement pursuant to Art. 53 LR…

GNW-Adhoc: Idorsia takes steps to address short-term liquidity needs

^Ad hoc announcement pursuant to Art. 53 LR * A bondholders meeting is expected to…

Idorsia: Aprocitentan Approval Is A Vital News

…

GNW-Adhoc: Idorsia thanks Guy Braunstein for his years of service as he retires

^* Guy Braunstein, currently Chief Medical Officer and member of the Idorsia Executive…

Idorsia thanks Guy Braunstein for his years of service as he retires

Allschwil, Switzerland – March 22, 2024Idorsia Ltd (SIX: IDIA) today announced that Guy Braunstein, who has served as Chief Medical…

GNW-Adhoc: US FDA approves Idorsia's once-daily TRYVIO (aprocitentan) - the first and only endothelin receptor antagonist for the treatment of high blood pressure not adequately controlled in combination with other antihypertensives

^Ad hoc announcement pursuant to Art. 53 LR * TRYVIO(TM) (aprocitentan) is indicated for the…

US FDA approves Idorsia’s once-daily TRYVIO (aprocitentan) – the first and only endothelin receptor antagonist for the treatment of high blood pressure not adequately controlled in combination with other antihypertensives

Ad hoc announcement pursuant to Art. 53 LR…

GNW-Adhoc: Idorsia and Viatris successfully close the transaction for the global research and development collaboration

^Ad hoc announcement pursuant to Art. 53 LR Allschwil, Switzerland - March 18, 2024 Idorsia Ltd (SIX: IDIA)…

Idorsia and Viatris successfully close the transaction for the global research and development collaboration

Ad hoc announcement pursuant to Art. 53 LR…

Idorsia surges 14% after securing $350M from Viatris in an R&D pact By Investing.com

Idorsia surges 14% after securing $350M from Viatris in an R&D pact…

GNW-Adhoc: Idorsia and Viatris enter into a significant global research and development collaboration

^Ad hoc announcement pursuant to Art. 53 LR * Viatris and Idorsia will collaborate on…

GNW-Adhoc: Idorsia presents at the J.P. Morgan Healthcare Conference - Adapting Idorsia for sustainable value creation

^Ad hoc announcement pursuant to Art. 53 LR * CEO, Jean-Paul Clozel, to update on…

GNW-Adhoc: New Phase 3 data with aprocitentan for patients with resistant hypertension has been presented at the American Society of Nephrology Kidney Week 2023

^Allschwil, Switzerland - November 3, 2023 Idorsia Ltd (SIX: IDIA) announced today that further data for aprocitentan, Idorsia's…

GNW-Adhoc: Idorsia gibt Finanzergebnisse für die ersten neun Monate 2023 bekannt - Anpassung des Unternehmens zur Schaffung von nachhaltigem Wert

^Ad-hoc-Mitteilung gemäss Art. 53 KR Allschwil, Schweiz - 24. Oktober 2023 Idorsia Ltd (SIX: IDIA) gab heute die…

GNW-Adhoc: Idorsia is committed to further the science of sleep with a symposium and poster presentations at World Sleep 2023

^Allschwil, Switzerland - October 23, 2023 Idorsia Ltd (SIX: IDIA) today announced that it is committed to…

GNW-Adhoc: Invitation to Idorsia's Nine-Month 2023 Financial Reporting webcast and conference call

^Idorsia will publish its Nine-Month Financial Reporting 2023 on Tuesday October 24, 2023, at 07:00 CEST. An investor…

GNW-Adhoc: Idorsia reacquires the world-wide rights to aprocitentan

^Ad hoc announcement pursuant to Art. 53 LR * Aprocitentan, Idorsia's oral, dual endothelin receptor…

GNW-Adhoc: Idorsia gibt Finanzergebnisse für das erste Halbjahr 2023 bekannt - Anpassung des Unternehmens zur Schaffung von nachhaltigem Wert

^Ad-hoc-Mitteilung gemäss Art. 53 KR Allschwil, Schweiz - 25. Juli 2023 Idorsia Ltd (SIX: IDIA) gab heute die…

GNW-Adhoc: Idorsia kündigt eine Kostensenkungsinitiative an, die bis Ende 2023 umgesetzt werden soll

^Ad-hoc-Mitteilung gemäss Art. 53 KR * Um Idorsia die nötige Zeit zu geben, um kommerzielle…

GNW-Adhoc: Idorsia sells its Asia Pacific (ex-China) operations - including select license rights to products - to Sosei Heptares for a total consideration of CHF 400 million

^Ad hoc announcement pursuant to Art. 53 LR Allschwil, Switzerland - July 20, 2023 Idorsia Ltd (SIX: IDIA)…

GNW-Adhoc: Invitation to Idorsia's HY 2023 Financial Results webcast and conference call

^Idorsia will publish its half year financial results 2023 on Tuesday July 25, 2023, at 07:00 CEST. An…

GNW-Adhoc: Idorsia announces its insomnia medication, QUVIVIQ (daridorexant), is now covered by CVS

^Ad hoc announcement pursuant to Art. 53 LR * The approximately 20 million US lives…

GNW-Adhoc: New Phase 3 data with aprocitentan for patients with resistant hypertension has been presented at the European Society of Hypertension Annual Meeting 2023

^Allschwil, Switzerland - June 26, 2023 Idorsia Ltd (SIX: IDIA) today announced that further data for aprocitentan, Idorsia's…

GNW-Adhoc: New Phase 3 data with aprocitentan to be presented at the European Society of Hypertension Annual Meeting 202

^Allschwil, Switzerland - June 23, 2023 Idorsia Ltd (SIX: IDIA) today announced that further data for aprocitentan, Idorsia's…

GNW-Adhoc: Idorsia has secured bridge financing in the amount of CHF 75 million

^Ad hoc announcement pursuant to Art. 53 LR Allschwil, Switzerland - June 20, 2023 Idorsia Ltd (SIX: IDIA)…

GNW-Adhoc: Idorsia bringt QUVIVIQ (Daridorexant) in der Schweiz auf den Markt - Erstes Medikament seiner Klasse für Behandlungen chronischer Schlaflosigkeit, das sowohl die nächtlichen Symptome als auch die Leistungsfähigkeit am Tag verbessert

^* QUVIVIQ(TM) wird angewendet zur Behandlung von Erwachsenen mit Schlafstörungen (Insomnie), deren Symptome…